Meda Pharma introduces 5ml nasal spray Rhinolast Allergy
Meda Pharmaceuticals has introduced 5ml nasal spray Rhinolast Allergy as an over-the-counter therapy to help children from the age of five tackle their hayfever misery.
Rhinolast Allergy is a non-steroid treatment and is suitable for children from as young as five years old.
Meda Pharma claims Rhinolast Allergy targets the symptoms of red, swollen and itchy eyes, runny nose and sneezing within minutes and can be used by children for up to four weeks without a doctor's intervention.
It contains the active ingredient azelastine which is more than just a simple anti-histamine.
It is the only anti-histamine with a triple mode of action, thus treating the disease and not just the symptoms.
Related Insight
Suppliers Directory
Hovione - API Development
When you really care about quality and performance, Hovione is your API
Hovione is an international company with over 50 years’ experience in API development and compliant manufacture. With FDA inspected sites in the US, China, Ireland, and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
Suppliers
Mayr-Melnhof - Sustainable Cartonboard Packaging Materials
Mayr-Melnhof Karton is the world's largest producer of coated cartonboard made from recovered fibre, and also holds an increasingly strong position in the production of virgin fibre-based board. MM Karton is a symbol for quality and reliability, competence and packaging safety.
Suppliers
Laminar Medica - Insulated Shipping Solutions
Laminar Medica is one of the world’s leading manufacturers of high performance passive insulated shipping solutions, supplying the pharmaceutical and biotechnology sectors for over 25 years.
Suppliers
Hapa - Late Stage Customisation and On Demand Printing Technologies
Hapa is the world leader in late stage customisation and on demand printing technologies for the pharmaceutical sector, delivering fast, accurate and value-creating packaging solutions.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Phenom™ G2 pro
Published by Phenom World
White Papers
Haselmeier Establishes New Pen Injector Assembly Facility in India
Published by Haselmeier
White Papers
Phenom™ use for pharmaceutical particle inspection
Published by Phenom World
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.